Austin American-Statesman - - LOCAL BRIEFING - Com­piled from staff re­ports

From Mary Ann Roser’s states­man. com/salud:

Scott & White’s Can­cer Re­search In­sti­tute in Tem­ple is seek­ing pa­tients to take part in a clin­i­cal trial test­ing an in­tra­venous drug that tar­gets ma­lig­nant T-cell lym­phoma, a type of blood can­cer.

The trial is open to peo­ple liv­ing in the Austin area who are will­ing to be hos­pi­tal- ized in Tem­ple for five days and are will­ing to re­turn to be mon­i­tored with lab work and/or clinic vis­its up to four times dur­ing the first 30 days. Pa­tients with par­tial or com­plete re­mis­sions will have fol­low-up vis­its dur­ing the year and an­nual vis­its to as­sess their re­sponse, ac­cord­ing to the re­search in­sti­tute.

About 15 per­cent of lym­phomas are of T-cell ori­gin, which tend to be chronic and do not re­spond well to chemo­ther­apy, ac­cord­ing to Dr. Arthur Frankel, di­rec­tor of the re­search in­sti­tute and of Scott & White’s di­vi­sion of hema­tol­ogy/on­col­ogy. Con­se­quently, the in­sti­tute is seek­ing new agents that can tar­get and kill the ma­lig­nant T-cells, such as this drug.

Scott & White’s has en­rolled 10 peo­ple in the study and hopes to en­roll up to 30 more. To be el­i­gi­ble, pa­tients must have failed pre­vi­ous treat­ment op­tions.

The trial is be­ing fi­nanced by the Gate­way for Can­cer Re­search foun­da­tion, a non­profit med­i­cal re­search phi­lan­thropy, ac­cord­ing to Frankel.

For in­for­ma­tion, con­tact clin­i­cal re­search co­or­di­na­tor Mar­garite Grable at

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.